Regarding safety precautions concerning the risk of developing interstitial lung disease that must be known before starting and during treatment with the medicinal product ERLOTINIB-VISTA

05.10.2022 1166 views

Щодо запобіжних заходів безпеки відносно ризику розвитку інтерстиціального захворювання легень, які необхідно знати до початку й під час лікування лікарським засобом ЕРЛОТИНІБ-ВІСТАPDF · 337 КБ

Завантажити

Regarding safety precautions concerning the risk of developing interstitial lung disease that must be known before starting and during treatment with the medicinal product ERLOTINIB-VISTA

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Regarding safety precautions concerning the risk of developing interstitial lung disease that must be known before starting and during treatment with the medicinal product ERLOTINIB-VISTA

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration